Giovanni Spagnolli
Co-Founder & Chief Technology Officer Sibylla Biotech srl
Giovanni Spagnolli is Chief Technology Officer at Sybilla Biotech, where he leads development of computational and structural biology platforms to identify druggable cryptic binding sites and enable novel therapeutic approaches. His expertise lies at the intersection of biophysics, computational biology, and drug discovery, with a focus on translating advanced scientific methodologies into scalable discovery technologies.
Seminars
Thursday 10th September 2026
Expansion Potential: Advancing Degradation into New Indications & Beyond “Classic” Degraders
8:45 am
- Highlighting innovations in non-E3 ligase mechanisms, and discussing which modality fits which disease class?
- Overcoming target identification bottlenecks for immunology and CNS targets. Should companies prioritize diseases with validated pathways but poor druggability, or tissues where degrader PK/ PD is already known?
- As pharma lean towards platforms with broad disease reach, what non-oncology data “moves the needle”?
